Bachem's Strategic Expansion Fuels Investor Optimism

Swiss pharma firm Bachem forecasts up to 45% revenue growth, backed by strong FY2025 results and major capacity investments to meet demand for peptide therapeutics.

The Swiss pharmaceutical firm Bachem, a leader in peptide-based therapeutics, is capitalizing on strong sector tailwinds. Following a robust performance in its 2025 fiscal year, the company's leadership has set an ambitious target, forecasting revenue growth of up to 45 percent for the upcoming period.

Analyst Perspectives and Market Performance

Market experts have responded with mixed, yet generally positive, assessments of Bachem's transition into a large-scale pharmaceutical player. UBS has raised its price target to 80 Swiss Francs, expressing confidence in the growth trajectory. In a more cautious stance, Vontobel maintains a target of 62 Francs.

Investors have welcomed the strategic direction, with the company's shares posting a weekly gain of 9.41 percent, closing at 61.30 GBP. Technical indicators suggest an intriguing setup: the Relative Strength Index (RSI) sits at 25.4, a level many market observers consider to be in technically oversold territory.

Financial Performance and Capacity Investments

Bachem's recent financial results underscore its current momentum. For the past fiscal year, revenue increased by nearly 15 percent to 695.1 million Swiss Francs. Profitability saw an even sharper rise, with EBITDA climbing almost 22 percent. This surge pushed the EBITDA margin to 30.9 percent, driven significantly by a nearly one-third increase in revenue from the clinical development of new active ingredients.

To meet sustained long-term demand, the company is embarking on a substantial infrastructure investment program. Capital expenditures exceeding 400 million Francs are planned for 2026. A cornerstone of this plan is the recent successful commissioning of a new production facility at its Bubendorf headquarters. Concurrently, capacity is being expanded at its US sites.

The efficiency with which the new capacities in Bubendorf and Vista can be utilized will be critical in the coming months. Achieving the ambitious 2026 growth objectives is heavily dependent on the timely completion of these ongoing construction projects.